Search Results for: DNA VACCINE TECHNOLOGY A Vaccine
Articles
Nuvec: A Breakthrough Technology for mRNA/pDNA Delivery for Vaccines & Cancer Treatments February 27, 2019
N4 Pharma Plc, a specialist pharmaceutical company, is developing Nuvec – a unique non-viral adjuvant delivery system for vaccines and...DNA VACCINE TECHNOLOGY - A Vaccine Breakthrough That Could Change Lives & Enable Vaccine Development Programs August 31, 2015
William Hearl, PhD, asks what if there was the potential for a better and safer treatment for allergies, a less-toxic cancer therapy, or a breakthrough treatment to improve the health of a pet or valuable livestock? What if you could employ a new, patented technology that may make these treatments possible?
Ethris & Lonza Collaborate to Develop Spray-Dried mRNA Vaccines for Respiratory Disease Prevention April 7, 2025
Ethris and Lonza reecently announced a collaboration to develop room-temperature stable, spray-dried formulations of mRNA-based vaccine candidates, designed for mucosal...VACCINE DEVELOPMENT - Enhancing Pandemic Preparedness With Mosaic-8b Nanoparticles February 10, 2025
Leonardo Magneschi, PhD, says although the mosaic-8b vaccine is still in early development, it has the potential to enable a broad and cross-reactive immunization strategy that could provide comprehensive protection against known and unknown sarbecoviruses.
Ocean Biomedical Advances Malaria Vaccine Research With New NIH Funding & Expedited Development Pathway January 29, 2025
Ocean Biomedical recently announced its Scientific Co-founder, Dr. Jonathan Kurtis, MD, PhD, and his research team have received additional significant...IMUNON Announces Site Activation for IMNN-101 Phase 1 Vaccine Study May 13, 2024
IMUNON, Inc. recently announced DM Clinical Research in Philadelphia is the first site activated and ready for patient recruitment for...ReciBioPharm Partners With Acuitas Therapeutics to Provide Rapid Technology Transfers & cGMP Manufacture of LNP Formulations December 12, 2023
ReciBioPharm, the advanced and emerging therapies business unit within Recipharm, and biotechnology firm Acuitas Therapeutics have recently announced they are taking their partnership to the next level….
Preclinical Data Shows Strong Immunogenicity & Protection With IMUNON’s PlaCCine DNA-Based Vaccines Modality August 7, 2023
IMUNON, Inc. recently announced a manuscript titled Strong immunogenicity & protection in mice with PlaCCine: A COVID-19 DNA vaccine formulated...VACCINE TECHNOLOGY - Solving the Challenges & Introducing New Strategies for Influenza & COVID-19 Protection May 1, 2023
Paul Radspinner, MBA, and Pamuk Bilsel, PhD, say with a combination vaccination strategy, the biopharma industry could truly solve the efficacy, durability, and drift problems of current influenza and COVID-19 vaccines.
Bhami Research Laboratory & Catalent Enter Licensing Agreement for Technology to Deliver High-Concentration Biologics Subcutaneously March 16, 2023
Bhami Research Laboratory (BRL) and Catalent recently announced a licensing agreement that will provide Catalent with access to BRL’s formulation...Pantherna & Evaxion Announce Promising Preclinical mRNA Vaccine Data February 8, 2023
Evaxion Biotech A/S and Pantherna Therapeutics GmbH recently announced preclinical proof of concept for the combination of the two companies’ key….
IMUNON Enters Collaborative Research Agreement With The Wistar Institute’s Vaccine & Immunotherapy Center to Research IMUNON’s PLACCINE Vaccine Platform January 5, 2023
IMUNON, Inc. and The Wistar Institute recently announced the signing of a first collaborative research agreement to research and develop new vaccine formulations utilizing IMUNON’s PLACCINE modality for the….
IMUNON Enters Technology Evaluation Agreement With Acuitas to Evaluate Placcine Plasmid DNA With Lipid Nanoparticle Delivery System November 10, 2022
Successful combination of technologies will expand the opportunities for IMUNON’s DNA-based modality and broaden applications for the PLACCINE nucleic acid vaccine platform as an alternative to mRNA and protein vaccines….
Evaxion Biotech Expands Its EVX-03 DNA Vaccine Program Into Non-Small Cell Lung Cancer June 23, 2022
Evaxion Biotech A/S recently announced it has selected EVX-03 as the product candidate within its DNA technology platform to target...Matinas BioPharma & BioNTech Announce Exclusive Research Collaboration to Evaluate Novel Delivery Technology for mRNA-based Vaccines April 11, 2022
Matinas BioPharma and BioNTech SE recently announced they have entered into an exclusive research collaboration to evaluate the combination of mRNA formats and….
Allergy Therapeutics Selects AGC Biologics to Manufacture Novel Peanut Allergy Vaccine Candidate March 31, 2022
AGC Biologics recently announced a new partnership with Allergy Therapeutics, the fully integrated specialty pharmaceutical company specializing in allergy vaccines. The...Celsion Corporation Advances Proof of Concept to Non-human Primate Challenge Study Against SARS-CoV-2 With In-Process Vaccine Candidate January 31, 2022
Celsion Corporation recently announced it has engaged BIOQUAL, Inc., a preclinical testing contract research organization, to conduct a non-human primate (NHP) challenge study with Celsion’s DNA-based approach for….
Provectus Biopharmaceuticals Provides Update on Research into PV-10 Immunotherapy as an Immune Adjuvant for Making Vaccines Work Better January 27, 2022
Provectus recently provided an update on research of its investigational immunotherapy PV-10 (rose bengal sodium, a halogenated xanthene small molecule)...Univercells Acquires SynHelix, Entering Into Synthetic Biology & the Race to Next-Generation DNA Synthesis January 6, 2022
Univercells S.A. (Univercells) recently announced its acquisition of SynHelix, a biotechnology company that aims to debottleneck biotherapeutics development through an unprecedented robust, scalable, and….
Celsion Reports T-cell & B-cell Response From In Vivo Studies With its PLACCINE DNA Vaccine Platform September 8, 2021
Celsion Corporation recently announced results from preclinical in vivo studies showing production of antibodies and cytotoxic T-cell response specific to...
